December 5, 2019

Results demonstrate target engagement and proof-of-mechanism Boston, Mass., December 5, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were presented at the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego by the principal investigator of the study, Professor […]

November 7, 2019

Results demonstrate target engagement and proof-of-mechanism Boston, Mass., November 7, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the REVERSE-SD study of neflamapimod in early-stage Alzheimer’s disease met its secondary objectives of target engagement and proof-of-mechanism demonstrating statistically significant reductions relative to placebo in cerebrospinal fluid (CSF) levels of phospho-tau […]

Phase 2 clinical trial of neflamapimod in patients with mild-to-moderate DLB currently enrolling patients in the U.S. and the Netherlands Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need Boston, Mass., November 7, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that […]

December 5, 2019

June 21, 2019

June 20, 2019